A beta-ray extracorporeal irradiator.
Explore the source record for details and available documents.
Biomedical subjects
Publications and source records attributed to C W Gilbert.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
BACKGROUND: This study was designed to assess the efficacy of polyethylene glycol(PEG) conjugated camptothecin, PEG-alpha-camptothecin, a novel water soluble transport form (prodrug) of the naturally derived antitumor drug, 20-(S)-camptothecin. MATERIAL AND METHODS: Circulatory retention studies were performed in non-tumor bearing mice injected intravenously with 300 mg/kg of PEG-alpha-camptothecin. Therapeutic efficacy was evaluated in both a murine P388/0 leukemia and a colorectal HT-29 carcinoma xenograft model. RESULTS: PEG-alpha-camptothecin had a blood t1/2 alpha of less than 5 minutes and a t1/2 beta of 3.5 hours. Five intraperitoneal injections of 3.2 mg/kg/day 20-(S)-camptothecin equivalents of PEG-alpha-camptothecin in our leukemia model resulted in significant survival over untreated controls (P < 0.001), with a mean time to death of treated versus control (T/C ratio) of 2.94 and a cure rate of 80% (n = 20). The colorectal carcinoma xenograft model demonstrated that 2-3 mg/kg/day 20-(S)-camptothecin equivalents of PEG-alpha-camptothecin given 5 days a week for 5 weeks could reduce an initial tumor burden of 300 mm3 by more than 90% without any signs of overt toxicity. CONCLUSION: This water soluble transport form of 20-(S)-camptothecin and its underlying technology may have clinical application.